Currently, there are 75.69M common shares owned by the public and among those 67.61M shares have been available to trade.
The company’s stock has a 5-day price change of 12.53% and -7.06% over the past three months. IDYA shares are trading 11.05% year to date (YTD), with the 12-month market performance up to 75.44% higher. It has a 12-month low price of $20.90 and touched a high of $47.74 over the same period. IDYA has an average intraday trading volume of 812.34K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 7.84%, 2.07%, and 7.05% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Ideaya Biosciences Inc (NASDAQ: IDYA) shares accounts for 97.60% of the company’s 75.69M shares outstanding.
It has a market capitalization of $2.99B and a beta (3y monthly) value of 0.86. The earnings-per-share (ttm) stands at -$2.00. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.16% over the week and 4.33% over the month.
Earnings per share for the fiscal year are expected to decrease by -16.35%, and 16.38% over the next financial year.
Looking at the support for the IDYA, a number of firms have released research notes about the stock. Mizuho stated their Outperform rating for the stock in a research note on Jul-09-24, with the firm’s price target at $50. BTIG Research coverage for the Ideaya Biosciences Inc (IDYA) stock in a research note released on March 08, 2024 offered a Buy rating with a price target of $55. SVB Securities was of a view on August 08, 2023 that the stock is Outperform, while Goldman gave the stock Buy rating on May 24, 2023, issuing a price target of $32. Stifel on their part issued Buy rating on April 24, 2023.
